

Evaluation of the PneumRx, Inc. Lung Volume Reduction Device for the Treatment of Emphysema.

Published: 16-03-2009

Last updated: 06-05-2024

To evaluate the safety and efficacy of the Lung Volume Reduction Coil to improve QOL pulmonary function for emphysema subjects with severe hyperinflation.

| | |
|------------------------------|---------------------------|
| Ethical review | Approved WMO |
| Status | Recruitment stopped |
| Health condition type | Respiratory disorders NEC |
| Study type | Interventional |

Summary

ID

NL-OMON35583

Source

ToetsingOnline

Brief title

LVR-Coil Safety Study

Condition

- Respiratory disorders NEC

Synonym

COPD, Emphysema

Research involving

Human

Sponsors and support

Primary sponsor: PneumRx, Inc

Source(s) of monetary or material Support: Industrie

Intervention

Keyword: Bronchoscopy, COPD, Emphysema, Lung volume reduction, Lung Volume Reduction Coil

Outcome measures

Primary outcome

Safety

Improvement in St. George's Respiratory Questionnaire (SGRQ) total score

Secondary outcome

Differences between baseline visit and 3 month follow-up visit

FEV1 (L)

RV/TLC (%)

Residual Volume (L)

Six minutes walk test (m)

modified Medical Research Council Dyspnea Scale (mMRC)

Oxygen use

Study description

Background summary

Current treatment of emphysema (COPD gold III-IV) generally is limited to palliative measures that include supplemental oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation or to lung transplantation. A small subset of patients with a heterogeneous pattern of emphysema might be benefited by lung volume reduction surgery, but this procedure is highly invasive and often results in high morbidity and mortality. A minimally invasive treatment with the potential to improve pulmonary function and reduce dyspnea in patients with homogeneous emphysema would provide meaningful clinical benefit.

Study objective

To evaluate the safety and efficacy of the Lung Volume Reduction Coil to improve QOL pulmonary function for emphysema subjects with severe hyperinflation.

Study design

Non randomized, multicenter, uncontrolled trial

Intervention

Nitinol Lung Volume Reduction Coils will be placed in both lungs during two bronchoscopic procedures, with an interval of 3 months because of safety follow-up, aiming to induce a volume reduction and therefore aiming to improve the clinical status of emphysema patients with severe hyperinflation by improving pulmonary mechanics.

Study burden and risks

The patients that will be screened for potential participation will receive pulmonary function testing, thoracic HRCT scanning (both are often already available) and an outpatient visit. The patients that will be included will have to come to our outpatient clinic, perform pulmonary function testing, a 6 min walking test, thoracic x-ray and testing of blood samples and arterial bloodgas. For the actual treatment with bronchoscopy under general anesthesia the patients will stay two times two days in our hospital. For the follow-up, 2 HRCT scans, 6 pulmonary function tests, six 6 min walking tests and 6 outpatient clinic visits will be needed

The included patients will have to put large effort in the study, but is in balance with the expected outcome and very limited compared 'alternative' treatments like highly invasive surgery: Lung volume reduction surgery or Lung transplantation. All included patients have a severe limitation of their activities of daily living. With the development and validation of the use of the airway bypass procedure does it seem possible to give -at least temporarily- relieve of shortness of breath and improvement in exercise performance. Furthermore can this technique be used as a 'bridge' to lungtransplantation in future, or will be the only possible therapeutic tool available by then. The risks are not bigger than the risks any individual has for the investigations described. The actual treatment with the LVR-Coils can cause: airway bleeding, airway infections and fever, pneumothorax, cough (that might result in an additional bronchoscopy to remove the coils), or death as a result of one of these complications.

Contacts

Public

PneumRx, Inc

530 Logue Avenue
Mountainview, CA 94043
U.S.A.

Scientific

PneumRx, Inc

530 Logue Avenue
Mountainview, CA 94043
U.S.A.

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Emphysema on HRCT-thorax
Post-bronchodilator FEV1 < 45% predicted
Total Lung Capacity > 100% predicted
mMRC dyspnea score >2
Stopped smoking > 8 weeks

Exclusion criteria

History of recurrent respiratory infections and/or bronchiectasis
Cardiovascular pathology
Inability to walk > 140 meters in 6 minutes

Giant bullae (> 1/3 lung volume)

Patient is taking > 20 mg prednisone (or similar steroid) daily

Patient has evidence of other disease that may compromise survival (such as lung cancer, renal failure etc)

Study design

Design

Study type: Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 14-04-2009

Enrollment: 20

Type: Actual

Medical products/devices used

Generic name: Nitinol Lung Volume Reduction-Coil

Registration: No

Ethics review

Approved WMO

Date: 16-03-2009

Application type: First submission

Review commission: METC Universitair Medisch Centrum Groningen (Groningen)

Approved WMO

Date: 17-06-2010

Application type: Amendment

Review commission: METC Universitair Medisch Centrum Groningen (Groningen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

| Register | ID |
|----------|----------------|
| CCMO | NL26560.042.09 |